Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14562836 | 1.00 | TDO2 (0.34) | TDO2CYP3A4PDE10A | |
| SCHEMBL16406106 | 0.79 | CYP3A4 (0.34) | TDO2CYP3A4PDE10A | |
| SCHEMBL16981769 | 0.77 | TDO2 (0.43) | TDO2CYP3A4PDE10A | |
| SCHEMBL13007521 | 0.77 | TDO2 (0.32) | TDO2 | |
| SCHEMBL14562851 | 0.75 | KDM4E (0.37) | CYP3A4PDE10A | |
| SCHEMBL5424182 | 0.75 | KDM4E (0.37) | CYP3A4PDE10A | |
| SCHEMBL5954903 | 0.75 | KDM4E (0.37) | CYP3A4PDE10A | |
| SCHEMBL22849475 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL3872536 | 0.74 | KDM4E (0.39) | CYP3A4PDE10A | |
| Hydrochloric Acid SCHEMBL3872534 | 0.74 | KDM4E (0.39) | CYP3A4PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | TDO2 3479/4885CYP3A4 1988/4885PDE10A 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.